 |
|
|
| |
Antiviral activity, pharmacokinetics, and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in a phase 1b study of patients with HBeAg positive chronic hepatitis B infection
|
| |
| |
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Kosh Agarwal1, Junqi Niu2, Edward Gane3, Tuan T. Nguyen4, Katia Alves5,
Marc Evanchik5, Hany Zayed5, Qi Huang5, Steven J. Knox5, Luisa M. Stamm5,
Richard Colonno5, Tarek I. Hassanein6, Dong Joon Kim7,
Young-Suk Lim8, Man-Fung Yuen9
1King's College Hospital Foundation Trust, London, UK;
2The First Hospital of Jilin University, Jilin, China;
3Auckland Clinical Studies Limited, Auckland, New Zealand;
4T. Nguyen Research and Education, San Diego, CA, US;
5Assembly Biosciences, Inc., South San Francisco, CA, US;
6Southern California Research Center, Coronado, CA, US;
7Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, South Korea;
8Asan Medical Centre, Seoul, South Korea;
9University of Hong Kong, Hong Kong, Hong Kong
|
| |
|
|
|
|
|
